Researchers Explore IV Magnesium's Role in Reducing Kidney Damage During Cisplatin Chemotherapy
In a recent study published in JAMA Oncology, researchers Shruti Gupta, MD, MPH, and David Leaf, MD, MMSc, from Brigham and Women's Hospital, have examined the potential protective effects of intravenous (IV) magnesium against kidney injury caused by cisplatin—a widely used chemotherapy drug. Their multicenter cohort study analyzed data from 13,719 patients who received their first dose of cisplatin between 2006 and 2022 across five major U.S. cancer centers. Notably, around 30% of these patients received IV magnesium on the same day as their cisplatin treatment.
Cisplatin is effective against various cancers but is known for its nephrotoxic side effects, which can lead to acute kidney injury. Current supportive care measures are limited, and there is a lack of robust clinical trial data on preventive strategies. Preclinical animal studies have suggested that magnesium may facilitate the excretion of cisplatin through urine, potentially offering renal protection. However, human studies have been scarce.
The researchers aimed to determine whether IV magnesium administration on the day of cisplatin infusion could decrease the risk of kidney damage. Their findings revealed that patients who received IV magnesium had a 20% lower adjusted risk of developing cisplatin-associated kidney injury compared to those who did not. These results remained consistent across various subgroup and sensitivity analyses.
The implications of this study are significant because magnesium is an inexpensive, accessible, and safe intervention. It could serve as a simple preventive measure to protect kidney function in patients undergoing cisplatin therapy. Despite promising evidence, the authors emphasize the need for randomized controlled trials to confirm these observations. Currently, such a trial is underway at Brigham and Women's Hospital.
This research highlights a potential strategy to mitigate one of the major side effects of cisplatin, ultimately improving patient outcomes. Further studies are warranted to establish definitive clinical guidelines for magnesium supplementation during cisplatin treatment.
Source: https://medicalxpress.com/news/2025-04-qa-discuss-iv-magnesium-kidney.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Extensive Snakebites by Man Could Lead to Breakthrough in Antivenom Development
A man who has been bitten by snakes 200 times may hold the key to developing a universal antivenom, potentially saving thousands of lives worldwide through innovative antibody research.
The Surprising Link Between Bacon, Feces, and Feelings of Disgust
Explore the fascinating psychological reasons behind why foods like bacon and feces evoke similar feelings of disgust, especially in vegetarians, and how this influences dietary choices.
Breakthrough in Multiple Myeloma Treatment: Single-Dose CAR-T Therapy Shows Long-Term Promise
A recent study demonstrates that a single infusion of CAR-T therapy cilta-cel can induce long-term remission in patients with relapsed multiple myeloma, with one-third remaining in remission for over five years. This milestone highlights the potential curative role of CAR-T in blood cancer treatment.
The History Encased in Every Tick Bite: Understanding Their Environmental and Epidemiological Significance
Explore how human actions and environmental changes over the centuries have transformed ticks into significant vectors of disease, revealing a complex history hidden in every bite.